Tue, Sep 16, 2014, 3:26 AM EDT - U.S. Markets open in 6 hrs 4 mins


% | $
Quotes you view appear here for quick access.

Biodel Inc. (BIOD) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • isaa0113 isaa0113 Sep 27, 2011 10:50 AM Flag

    Seems funny...

    hope so. Although chief medical officer and another director sold a couple of days ago ahead of the results. The problem was the wash-out phase in the RHI 105 & 107. Data wasn't bad, but I think they know their is really no hope to bring those into a phase II. Maybe they have other RHI's to look at, but bottom line is I don't think they felt comfortable with wash-out phase. Analogs are last hope and data in swine looks really good. If I'm one of big three and I see that data I take a chance and bring my analog into the clinic with Biodel's formulations to test on humans. Especially when my patents are expiring in the next 2-4 years.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • isaa,

      I think you hit it right on the head with your post. There are a lot of nonsense posts today (even among the longs), but what isaa is saying is what the reality is. That's what I've thought for some time and why I said the results today didn't matter, the analog formulations are the end game here. BIOD is holding some cards though b/c the patents are expiring for analog cos. As Desouza said in the Q&A this morning and this is VERY IMPORTANT, "it is not data holding us back (with the analog formulations) it is the business arrangement". Basically they are just making sure they get a good deal for BIOD shareholders. But they can always use API from India source and move the analogs to the clinic. Just more desirable to partner with analog pharma now and get the validation/financing to ensure success.

1.82-0.07(-3.70%)Sep 15 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Avanir Pharmaceuticals, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
21Vianet Group, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
JDS Uniphase Corporation
NasdaqGSMon, Sep 15, 2014 4:15 PM EDT